Innovation of care through clinical trials can open doors to hope, discover possibilities and change lives.
At Onvida Health, we do more than provide the latest in modern medicine – we aim to advance it. Through clinical trials, our providers find ways to improve treatment options and quality of life.
Trials are designed to explore innovations that may prevent, treat, find and diagnose disease, as well as manage symptoms and side effects of treatment, leading to better outcomes for you.
These medical advances are available at Onvida Health, so there is no need to travel for access to many clinical trials. With the vast diversity of the population we serve, we can offer trials that may not be available elsewhere. Patients who decide to participate in clinical trials can expect the highest level of care and treatment in a compassionate and supportive environment.
Current Clinical Trials
Below are the clinical trials we are currently offering at Onvida Health in cancer care and cardiology. If you are interested in participating in a clinical trial, please call 928-336-2972 or e-mail us at YRMCResearch@yumaregional.org.
Cancer
Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases
Study Identifier: P4M060
Sponsor: Precision for Medicine
Closed to enrollment
Principal Investigator: Abhinav Chandra, M.D.
Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
Study Identifiers: MT1410-A, MT0221, MT0291
Sponsor: MT Group
Open to enrollment
Principal investigator: Abhinav Chandra, M.D.
If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at Onvida HealthResearch@yumaregional.org.
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After the Same-Day, Varying Dosing Time Schedules of Eflapegrastim Administration in Patients with Breast-Cancer Receiving Docetaxel and Cyclophosphamide
Study identifier: SPI-GCF-104
Sponsor: Spectrum Pharmaceuticals, Inc.
Open to enrollment
Principal investigator: Angela Saverimuthu, M.D.
Open-label, Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Study identifier: Sermonix Elaine II
Sponsor: Pfizer
Closed to enrollment
Principal investigator: Angela, Saverimuthu, M.D.
If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at Onvida HealthResearch@yumaregional.org.
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Study identifier: Stimulus MDS-2
Sponsor: Novartis Pharmaceuticals
Closed to enrollment and active patient
Principal investigator: Arun Raajasekar, M.D.
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)
Study identifier: DREAMM 7
Sponsor: GlaxoSmithKline
Closed to enrollment and active patient
Principal investigator: Abhinav Chandra, M.D.
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)
Study identifier: DREAMM 9
Sponsor: GlaxoSmithKline
Closed to enrollment
Principal investigator: Abhinav Chandra, M.D.
If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at Onvida HealthResearch@yumaregional.org.
Open-label, Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Study identifier: Pharos
Sponsor: Pfizer
Closed to enrollment
Principal investigator: Vaddepally Raju, M.D.
If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at Onvida HealthResearch@yumaregional.org.
The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment
Study identifier: OMS-I103 PISCES
Sponsor: OncoSec Medical Incorporated
Open to enrollment
Principal investigator: Abhinav Chandra, M.D.
If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at Onvida HealthResearch@yumaregional.org.
Cardiology
Assessment of Primary Prevention Patients Receiving An ICD – Systematic Evaluation of ATP
Study Identifier: APPRAISE ATP C1924
Sponsor: Boston Scientific Corporation
Closed for enrollment and active patients
Principal Investigator: David Meyer, M.D.
If you are interested in participating in this clinical trial, please call 928-336-2972 or e-mail us at Onvida HealthResearch@yumaregional.org.
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon (TRANSCEND)
Study Identifier: Surmodics Transcend SUR17-011
Sponsor: SurModics, Inc.
Closed for enrollment
Principal Investigator: Joseph Cardenas, M.D.
If you are interested in participating in one of these clinical trials, please call 928-336-2972 or e-mail us at Onvida HealthResearch@yumaregional.org.
